Acamprosate for Alcohol Use Disorder

"Acamprosate, FDA approved for treatment of AUD in 2004, is believed to stabilize the neurochemical imbalance in γ-aminobutyric acid (GABA) and glutamate neurotransmitter systems that develop with sustained heavy alcohol use. Acamprosate is administered as 2 tablets 3 times daily or 1 tablet 3 times daily for a glomerular filtration rate of 30 to 50 mL/min/1.73 m2. Acamprosate is safe for patients with Child-Pugh class A and B cirrhosis, but is contraindicated if the glomerular filtration rate is less than 30 mL/min/1.73 m2."

Source

Holt SR. Medications for Alcohol Use Disorder. JAMA. Published online August 19, 2026. doi:10.1001/jama.2026.10575